On March 7, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Omlyclo® (omalizumab-igec) as the first interchangeable biosimilar to Novartis’ Xolair® (omalizumab). Omlyclo is approved for the same indications as ...

The US Food and Drug Administration (FDA) has determined the shortage of glucagon-like peptide 1 (GLP-1) medication, semaglutide, is resolved. Semaglutide injection products have been on the FDA shortage list since 2022. The FDA ...

The 2023 United States Preventive Services Task Force (USPSTF) recommendation for PrEP specifically cites the three medications currently approved by the FDA for use as PrEP. Therefore, it is the position of The Departments, as outlined in FAQ…

Doctors and pharmacists are allowed to compound drugs for individual patients when the compounded drug is not commercially available. Licensed outsourcing facilities (LOF) can compound at a higher volume but can only do so in…

Notable industry trends throughout 2024 include the continued growth of the specialty market. Across the industry, specialty medications now account for an estimated 54% of spending which has been driven mainly by…